Key Points {#FPar1}
==========

Chimeric antigen receptor-T cell (CAR-T) therapy for the treatment of solid tumors is currently being evaluated in approximately one-third of all CAR-T clinical trials.CAR-T therapies targeting solid cancers have yet to demonstrate similar levels of clinical response as those being achieved in hematological indications.Developing methods and technologies to overcome the immune-suppressive tumor environment, tumor accessibility and infiltration, as well as optimization of CAR-T function are the current focus of the CAR-T field in order to improve therapy for solid tumors.

Introduction to the Chimeric Antigen Receptor-T Cell (CAR-T) Field {#Sec1}
==================================================================

Chimeric antigen receptors (CARs) are artificial fusion proteins that, when expressed on the cell surface, endow the engineered T cell with a pre-defined target specificity \[[@CR1]\]. The CAR itself has developed through several generations, albeit generally based on the same configuration: an extracellular antigen-binding domain, usually employing an antibody-derived single-chain variable Fragment (scFv), linked through an extracellular spacer to a transmembrane domain and an intracellular T cell activation tail comprising different functional units. The core component of the CAR endodomain typically consists of the intracellular domain of the T cell co-receptor CD3ζ containing three immunoreceptor tyrosine-based activation motifs (ITAMs) in tandem with, depending on the generation, none, one, or two co-stimulatory domains. Upon expression in a T cell, the CAR can engage its target antigen and thereby enable the lymphocyte to activate a plethora of effector responses resulting in targeted cell killing \[[@CR2]\].

Whilst T cells use their endogenous T cell receptor (TCR) to bind specific proteins on target cells called the major histocompatibility complex (MHC), the expression of the CAR avoids this restriction and provides the real power to the approach in which the T cell can be directed to virtually any tumor target without MHC restriction. Consequently, while tumors evolve to avoid immune elimination through utilizing mechanisms that subvert the activity of the TCR, the CAR employs a targeting approach that in turn 'avoids the avoidance mechanism', making tumors again susceptible to T cell-mediated attack. Together, the breadth of targeting combined with the generic nature of the approach for any patient, given the lack of reliance on MHC, makes the CAR approach a potentially highly attractive therapy.

The reason why the approach is 'potentially' attractive relates to the target and the barriers that the CAR-T cell (CAR-T) has to overcome to engage and eliminate tumor cells. An ideal target is one that is highly expressed on transformed cells as compared to low or undetectable levels of expression on non-malignant healthy tissues. Yet, for the most part, such perfect targets do not exist due to the lack of truly tumor-specific targets. The targets most commonly available are typically over-expressed on transformed cells but also expressed at low levels on non-malignant tissues meaning that 'on-target, off-tissue' toxicity becomes a limiting factor. In the B cell situation, the CD19 target antigen is expressed solely on B cells meaning that the CAR-Ts will eliminate malignant and non-malignant B cells. Whilst clearly not ideal, the lack of B cells is not considered to be life-threatening, with patients receiving immunoglobulin infusions to counter the lack of B cells in the treated patient.

To date, the most clinically investigated indications for CAR-T therapy are hematological malignancies \[[@CR3], [@CR4]\] (Fig. [1](#Fig1){ref-type="fig"}). CD19-directed CAR-T therapy has demonstrated impressive clinical responses in patients with advanced, chemotherapy-resistant leukemia and lymphoma, reaching up to 70--90% of minimum residual disease-negative complete remissions in some studies \[[@CR5]--[@CR8]\]. Two CD19-specific CAR-T treatments were recently approved by the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA), namely Yescarta™ (axicabtagene ciloleucel) \[[@CR9], [@CR10]\] for patients with relapsed or refractory aggressive non-Hodgkin lymphoma and Kymriah™ (tisagenlecleucel) \[[@CR11], [@CR12]\] for patients with acute lymphoblastic leukemia and diffuse large B cell lymphoma \[[@CR13], [@CR14]\]. The success story of CAR-T therapies in hematological malignancies has nurtured the hope of extending the use of these 'living drugs' to further cancer indications, including solid tumors, especially considering the proportion of new cases of patients with solid tumors per year as compared with hematological tumors (Fig. [1](#Fig1){ref-type="fig"}).Fig. 1Estimated proportion of new cancer cases in the USA in 2019 (left) and CAR-T clinical trials per organ class (right). Based on Cancer Facts and Figures, 2019 (American Cancer Society) \[[@CR129]\] and the U.S. National Library of Medicine (ClinicalTrials.gov; excluding long-term follow-up and retrospective studies). *CAR-T* chimeric antigen receptor T cell

When considering the majority of solid tumors, much effort is ongoing worldwide to determine patient-specific antigens (neo-antigens) that can be targeted, but this approach is not well-suited to the generic CAR-T approach where a single CAR can be used in the majority of patients with a specific tumor indication. Consequently, many of the targets in current use for solid tumor CAR-T therapy have been identified through antibody-directed therapies and are usually expressed to some degree on non-malignant tissue. As discussed later, this means either titrating the CAR-T therapy to achieve a window of therapy without toxicity or the development of methods that can more directly control the CAR itself to negate the possibility of on-target, off-tissue toxicity.

Beyond the question of target, there is increasing clarity concerning the specific challenges raised by solid tumors to CAR-T therapy. This review discusses these major obstacles and explores preclinical and clinical efforts aiming to overcome these hurdles and drive the success of CAR-T therapy in the solid cancer area where, to date, substantive levels of clinical response are still lacking (see Sect. [3](#Sec9){ref-type="sec"}).

Overcoming the Barriers Raised by Solid Tumors Against T Cells {#Sec2}
==============================================================

The impressive clinical response of CD19-specific CAR-T likely relies on the high-level expression of the targeted antigen on the tumor cells as well as the peripheral distribution of the lymphoid cancer cells enabling accessibility and susceptibility to T cell-mediated elimination. Unlike B cell malignancies, solid cancers sculpt a tumor microenvironment (TME) that not only restricts lymphocyte trafficking and access to the entire mass of the solid tumor \[[@CR15]\] but also downregulates their activity, expansion, and persistence at the tumor site \[[@CR16], [@CR17]\]. The TME represents an intricate cellular and molecular immunosuppressive network formed by aberrant vasculature, stromal cells, immune cells (including regulatory T cells \[Tregs\]/myeloid-derived suppressor cells \[MDSCs\]/tumor-associated macrophages \[TAMs\]), and extracellular matrix-containing inhibitory factors, and is characterized by oxidative stress, nutritional depletion, acidic pH, and hypoxia \[[@CR18]\]. Beyond the immunosuppressive TME and the paucity of uniquely and homogeneously expressed tumor antigens, the inherent plasticity of cancer cell populations and the selective outgrowth of target antigen-loss variants add an additional layer of complexity, providing further challenges to the effectiveness of CAR-T therapies.

To face those challenges, additional engineering of CAR-Ts and the use of combination therapies hold the potential to endow therapeutic cell products with novel attributes necessary to overcome immunosuppressive aspects of the TME. However, since solid tumors are protected from immune attack by cumulative defenses, the abrogation of only one factor may not produce a significant change in the effectiveness of the overall cellular immunotherapy. Moreover, it is crucial that efforts to enhance the functionality of CAR-Ts do not compromise safety and should ideally be coupled with stringent tools that allow for spatial and temporal control of their activity and persistence after deployment into the patient \[[@CR19]\].

The following sections describe some of the approaches that are being considered to surmount challenges faced when treating solid tumors with CAR-T therapies, with a focus on strategies that concurrently resolve more than one evasion mechanism and that are widely applicable to different solid tumor indications.

Increasing the Homing of CAR-Ts at the Tumor Site {#Sec3}
-------------------------------------------------

Following infusion into the systemic circulation, CAR-Ts are faced with the immediate obstacle of localizing to and infiltrating into the tumor parenchyma. Homing and tissue infiltrating is a multistep process governed by the expression and pairing of adhesion molecules present on both the T cells and the inflamed vasculature that act sequentially to mediate attachment, rolling, and extravasation of circulating lymphocytes towards a chemokine gradient produced by tumor cells. However, aberrant expression of adhesion molecules on the tumor endothelium as well as T cell chemokine receptor/tumor-associated chemokine incompatibility and hydrostatic pressure result in inefficient intratumoral T cell infiltration potentially causing treatment-related toxicities due to the accumulation of transferred cells in inflamed normal tissues, such as in the case of injury or autoimmune disease \[[@CR20]\].

Several preclinical models demonstrated that the forced expression of a chemokine receptor complementary to tumor-associated chemokines enhanced the ability of CAR-Ts to traffic to and expand at the tumor site, consequently improving their antitumor efficacy \[[@CR21], [@CR22]\]. However, applicability of this approach is restricted by the fact that the chemokine landscape can be extremely heterogeneous both across disease entities and patients, underscoring the need to identify specific receptor candidates to enhance T cell infiltration into different cancer types \[[@CR23]\]. Furthermore, chemokines are not restricted to the tumors, suggesting there could be diversion of the cells to other anatomical locations where the specific chemokine is present.

Although not always technically achievable, loco-regional delivery of CAR-Ts reduces trafficking restrictions without additional engineering while circumventing the transient pulmonary sequestration of intravenously administered T cells \[[@CR24], [@CR25]\]. In mouse models, intraperitoneal or intrapleural administration of CAR-Ts outperformed systemic infusion and, surprisingly, also impacted disseminated tumor sites attributed to a benefit of T cell activation shortly after delivery \[[@CR26], [@CR27]\]. Accordingly, several clinical trials are examining the safety of administration of loco-regional CAR-T therapies (discussed in Sect. [3](#Sec9){ref-type="sec"}), even though infiltration within solid tumor masses is not always improved by loco-regional delivery. Finally, nanoparticles expressing CARs, which bind to and re-program peripherally circulating T cells in vivo, were also recently developed to increase selectivity and distribution to distant organs \[[@CR28]\].

Neutralization of Immunosuppressive Mediators within the Tumor Microenvironment {#Sec4}
-------------------------------------------------------------------------------

Once they have successfully invaded the tumor parenchyma, CAR-Ts then have to contend with a highly hostile milieu for T cell antitumor effector function, replete with suppressive mediators (transforming growth factor \[TGF\]-β, interleukin \[IL\]-10, IL-4) and inhibitory molecules (programmed death-ligand 1 \[PD-L1\], cytotoxic T lymphocyte antigen 4 \[CTLA-4\], Fas-ligand \[FASL\]). Apart from TME remodeling, which should be induced by the combination with chemotherapy agents, a more specific combination strategy with programmed death 1 (PD-1)/PD-L1 or CTLA-4-blocking antibodies (the so-called checkpoint inhibitors commonly used in clinical studies with excellent outcomes \[[@CR29]\]) and CAR-Ts can therefore potentially augment antitumor effects against solid tumors \[[@CR17], [@CR30], [@CR31]\]. CAR-Ts can also be shielded to intrinsically resist immunosuppressive signaling by disrupting endogenous expression of inhibitory receptors through gene editing or transgenic expression of a dominant-negative form of those receptors or inhibitory antibodies \[[@CR32]--[@CR36]\]. However, the abrogation of immunosuppressive signaling may be insufficient, prompting additional investigations into alternative approaches that can turn TME limitations into advantages for the transferred CAR-Ts. Co-expression of a chimeric receptor that converts an immunosuppressive signal into an immunostimulatory one could also extend CAR-T engineering beyond neutralization of inhibitory ligands to the active reversal of their effects. Exchanging the endodomain of inhibitory receptors such as IL-4 receptor (IL-4R) or PD-1 with signaling domains derived from stimulatory receptors (IL-7 receptor \[IL-7R\], CD28, or 4-1BB) improved in vivo antitumor efficacy of tumor-directed T cells \[[@CR37]--[@CR39]\]. Importantly, CAR-T activation could be confined to the tumor site since triggering would require exposure to both the specific antigen and the tumor-derived factor. In addition to promoting function and survival of the modified T cells, the use of inhibitory-to-stimulatory switch receptors might present the advantage of depriving the TME of an immunosuppressive factor, potentially providing collateral benefits to endogenous exhausted tumor-infiltrating lymphocytes (TILs) \[[@CR39], [@CR40]\]. Although those additional engineering strategies proved effective in murine models, selective neutralization of a single immunosuppressive pathway might render a functional, albeit transient, antitumor state and fall short of preventing long-term relapse due to the upregulation of multiple inhibitory receptors by activated T cells, thus limiting the window of time that the CAR-Ts exert their function. On the other hand, as those receptors are important regulators of T cell homeostasis, the impact of such modifications on T cell effector function in humans remains to be determined, as well as any potential impact of the leverage of immune brake that could lead to uncontrolled lymphoproliferation or other immune-related adverse events.

Another methodology addresses the unfavorable TME by using CAR-Ts as production vehicles that secrete proinflammatory cytokines, such as IL-12 or IL-18, into the targeted tumor tissue, tuning the T cell response into a more acute one \[[@CR41]\]. Beyond auto-stimulation of the transferred cells \[[@CR42]\], release of effector cytokines by those so-called 'TRUCKs' (T cells Redirected for Universal Cytokine Killing) was shown to reshape the TME through multiple paracrine mechanisms including recruitment of additional tumor-reactive cells from the innate and adaptive immune systems \[[@CR43]--[@CR45]\]. As tumor cell lysis by TRUCKs can generate new antigen-specific lymphocytes via epitope spreading, the concomitant local release of effector cytokines will support the effector function of these host immune cells and also recruit and activate innate immune cells \[[@CR46], [@CR47]\]. Despite all the expected benefits, the systematic delivery of proinflammatory cytokines may lead to significant toxicities \[[@CR48]\], underscoring the critical need to restrict cytokine production to the lesion site by using a promoter that becomes active only upon CAR engagement. In addition, inducible expression systems are more likely to constrain cytokine levels within a therapeutic range as overactivation of T cells by supra-therapeutic cytokine levels will foster counterproductive exhaustion. However, in early-phase clinical trials, adoptive transfer of TILs genetically engineered to secrete IL-12 at the tumor site resulted in severe toxicities \[[@CR49]\]. Therefore, the use of less stimulatory cytokines such as IL-18 might present a safer option as this cytokine was given intravenously at high biologically active doses to cancer patients with no occurrence of dose-limiting toxicities \[[@CR50]\]. In addition, integration of suicide genes or safety switches is another option to mitigate toxicity potentially induced by such strategies (see Sect. [2.5](#Sec7){ref-type="sec"}).

Since emerging nanoscale-targeted drug carriers are able to remodel the TME without giving rise to the systemic toxicity, CAR-engineered T cells were also employed as active chaperones to successfully deliver adenosine receptor antagonist-loaded cross-linked multilamellar liposomal vesicles to TILs deep in the immunosuppressive TME, in order to prevent or rescue the emergence of hypofunctional CAR-Ts within the TME \[[@CR51]\].

Boosting In Vivo CAR-T Expansion and Persistence Capacities {#Sec5}
-----------------------------------------------------------

While the in vivo cell expansion and effectiveness of CD19 CAR-Ts seem to correlate in certain studies using CAR-T in hematological malignancies \[[@CR52], [@CR53]\], it is generally considered that the intrinsic qualities of infused lymphocytes are some of the determinants of success in CAR-T therapies. The ex vivo manipulation of T cells provides a unique opportunity to select for cellular subsets with enhanced potential for mounting durable antitumor responses \[[@CR54]\]. Selection of CD8^+^ cytotoxic cellular subsets, ratios of CD4:CD8, or use of natural killer cells may increase broad effector activity \[[@CR46], [@CR55]\]. Although the 'seed' population optimally suited for the production of long-lived CAR-Ts is still a matter of debate, an emerging consensus postulates that less-differentiated phenotypes such as cells presenting naïve and central memory phenotypes have superior proliferative capacity and sustained survival and, as such, are more effective at regressing established tumors than late-differentiated effector memory and effector T cells \[[@CR56]\]. Building on this concept, there is growing interest in developing protocols to conduct large-scale T cell amplification, while simultaneously preserving the functional features of early-memory T cells \[[@CR57]\]. It was shown that reducing the duration of ex vivo culture to 3--5 days yielded less-differentiated cells with enhanced therapeutic potential compared with cells expanded using standard 9- to 12-day protocols \[[@CR58]\]. An alternative strategy to limit cell differentiation during CAR-T manufacturing is the pharmaceutical blockade of the phosphoinositide 3-kinase (PI3 K)/AKT axis playing an integral role in T cell activation downstream of the TCR and co-stimulatory molecules \[[@CR59], [@CR60]\]. Another option would be to substitute IL-7 and IL-15 for IL-2 as the growth factor support during ex vivo generation of CAR-T products as this cytokine combination was shown to enrich for T memory stem cells \[[@CR61]\]. In preclinical models, CAR-Ts expanded in IL-7 and IL-15 showed superior persistence and antitumor activity compared with counterparts grown in IL-2 \[[@CR62]\].

Holding back the acquisition of full effector capacity ex vivo by the reduction of culture duration or modulation of T cell differentiation represents relatively easily translatable and widely applicable ways for the generation of early-memory CAR-Ts. The question is whether these cells have the therapeutic potential to be effective at lower infusion doses, potentially mitigating acute toxicity and commensurately trimming production costs \[[@CR60]\].

The evolution of CAR design, to date, has focused predominantly on increasing signaling outputs through combinatorial modules of co-stimulatory domains fused in series to ITAM-bearing CD3ζ activation domain \[[@CR63]\]. However, there is now a growing appreciation that functional tuning of CAR signaling has an upper limit. Above this limit, gains in the magnitude of effector outputs are negated by augmentation of T cell differentiation, exhaustion, and activation-induced cell death (AICD) \[[@CR20], [@CR21]\]. Accordingly, the next challenge for future CAR generations will be to calibrate CAR activation in order to achieve an optimal balance between effector and memory programs in T cells. Optimized configurations of CARs are being investigated to better recapitulate the dynamic process of natural T cell activation and co-stimulation, sharply differing from the 1:1 stoichiometry constraint within CAR designs currently under clinical investigation. For example, the expression of a CD28-based CAR along with 4-1BB ligand resulted in higher therapeutic efficacy, reconciling tumoricidal function afforded by CD28 co-stimulation with increased T cell persistence afforded by 4-1BB engagement \[[@CR64]\]. Recently, a CD28-based CAR containing a single functional ITAM was shown to favor in vivo persistence of highly functional CAR-Ts, balancing the replicative capacity of long-lived memory cells with the acquisition of strong antitumor effector functions \[[@CR65]\]. However, the optimal construct will likely depend on several factors, including affinity (avidity) for target, tumor access, and the type of TME.

Therefore, while several options to improve both persistence and expansion capacities of CAR-Ts are currently being investigated, no universal solution has yet been identified. To this end, the empirical testing of CARs remains the only option to evaluate the different potential schema of CAR/T cell phenotype/additional functionality such as TRUCKs.

Improving Targeting of Heterogeneous Tumors {#Sec6}
-------------------------------------------

Although not specific to solid tumors, due to the paucity of truly tumor-restricted antigens in solid tumor tissues, CAR-Ts will need to become capable of recognizing patterns of gene expression that are different between normal and malignant cells, rather than relying on single---though highly specific---antigenic markers. One approach that was investigated is to engineer CAR-Ts with dual specificity, whereby two receptors targeting distinct antigens act as 'AND/NOT' Boolean logic gates \[[@CR66], [@CR67]\] in order to prevent toxicity while maintaining efficacy, rather than irreversibly deleting CAR-Ts that are toxic against both tumor and host. The 'AND' gates require the successful recognition of a set of pairwise upregulated tumor antigens by two different CARs to initiate full immune cell functions \[[@CR68], [@CR69]\], whereas 'NOT' gates employ receptors that prevent T cell activation when engaging antigens found on healthy tissues \[[@CR70]\]. While Boolean logical sensing may enhance the specificity of CAR-Ts towards tumors, this approach is still limited by the fixed antigen specificity of conventional CAR design, and by the fact that the therapeutic window will require an optimal expression pattern of multiple targets while a single target antigen loss could severely disable the system.

An alternative to this classical antibody-based CAR limitation would be to harness the multiple ligand-binding ability of physiological immune receptors such as NKG2D (natural killer group 2 member D). NKG2D recognizes several stress-induced ligands expressed within the TME of cancers from diverse origins, not only on the tumor cells themselves but also on tumor neovasculature and tumor-associated immune cells. Thus, a CAR bearing NKG2D as the targeting moiety holds the potential to eliminate a broad array of cancers, simultaneously altering the tumor and its supportive framework \[[@CR71]--[@CR73]\]. A second ligand-based CAR approach targets the ErbB receptor family, for which at least one member is expressed in 88% of solid tumors \[[@CR74]--[@CR77]\].

Another possibility is to target the CAR-Ts towards antigens expressed on tumor stroma and vasculature, which are expressed by multiple tumor types and would increase the homing into the TME \[[@CR78], [@CR79]\].

Mitigating Toxicity {#Sec7}
-------------------

A first option to mitigate the potential on-target, off-tissue toxicity of CAR-Ts is the use of CAR-Ts with reduced persistence capacities such as transiently expressed CARs using non-viral approaches including messenger RNA (mRNA) electroporation \[[@CR80]\], sleeping beauty transposition \[[@CR81]\], and/or a multiple-dose schedule of short persisting CAR-Ts to control engraftment \[[@CR80], [@CR82]\]. Furthermore, the hypofunctionality of CAR-Ts within the TME may also be overcome by a multiple-dosing approach \[[@CR16], [@CR17], [@CR83]\].

Equipping CAR-Ts with properties aimed at enhancing their potency or their infiltration into tissues should ideally be coupled with stringent safety attributes that allow for temporal regulation of activity or persistence of infused cells in the patients. Co-expression of suicide genes encoding surface molecules or enzymes conferring susceptibility to antibody- or drug-mediated cell death allows for selective and irreversible depletion of the transduced T cells after infusion into the patients \[[@CR84]--[@CR86]\].

To avoid the irrevocable elimination of potentially therapeutic cells, several platforms have been developed to repeatedly turn on and off CAR-T activity at will after re-infusion into the patients (called 'safety switch' or 'advanced cell programming technology') to prevent and/or limit the likelihood of toxicity. These 'switchable' CAR-Ts are not directed to a cell surface target antigen and are per se inert but become operative strictly in the presence of a bispecific adaptor molecule that mediates formation of the immunological synapse between the target cancer cell and the lymphocyte \[[@CR87]--[@CR92]\]. After rapid elimination of the adaptor molecule from the peripheral blood, CAR-Ts automatically turn off, thus providing a self-limiting safety switch. Moreover, the modularity of the switchable CAR-T approach provides options for altering specificity post-adoptive transfer by delivery of adaptor molecules targeting different antigens together with one single cellular product, which may be an effective strategy for addressing antigen loss relapse and heterogeneity of tumor populations. Furthermore, the ability to titrate CAR-T activity in vivo through adaptor molecule dosing paradigms offers the opportunity to achieve a gradual clearance of cancer cells, minimizing acute toxicity in high tumor burden patients. Finally, low-dose treatment with an adaptor molecule maintained a larger central memory compartment within CAR-Ts than did high-dose regimens, with the potential to boost in vivo cell endurance, as discussed earlier. However, the potential drawback of this approach lies in the need for multiple costly reagents and the challenge of ensuring that the engager and CAR-T meet in the correct location at a concentration of each entity sufficient to drive a therapeutic response. Within the parenchyma of a solid tumor, this would likely be a major dosing challenge.

Combination of Approaches into One Cellular Product {#Sec8}
---------------------------------------------------

The future of CAR-T cellular therapies for solid tumors resides in the alliance of wisely selected complementary approaches that will generate a cellular product with enhanced tissue penetration and homing, well-balanced effector and memory outputs, enhanced specificity/safety, and the ability to resist TME immunosuppression while concurrently reviving the endogenous host immune system (see Table [1](#Tab1){ref-type="table"}). Using healthy donor cells instead of each patient's cells, i.e., development of allogeneic approaches with a decreased risk of graft-versus-host disease (GvHD) and management of host-versus-graft disease (HvGD), may provide answers to some of these issues. The use of a single donor should provide a greater degree of product consistency, while the likely youthful healthy donor would potentially provide a T cell product that has not been skewed by the long-term exposure to tumor cells as would be the case for an autologous product. From a practical perspective, allogeneic CAR-T therapy may also provide economic benefits through reduced per patient costs and the fact that patients would not need to wait for the length of the manufacturing period before receiving the product. Earlier treatment of patients with acute disease could be of critical importance with respect to therapeutic readouts. One approach being pursued to generate an allogeneic CAR-T product is the complete elimination of TCR and human leukocyte antigen (HLA) molecules usually performed by gene-editing techniques \[[@CR93], [@CR94]\].Table 1Strategies for chimeric antigen receptor-T cells to surmount hurdles specific to solid tumorsApproachesBenefitsImproved homing to tumor siteTME modulationEnhanced in vivo expansionMitigated toxicityAddressing tumor heterogeneityWidely applicable (translatable to clinic)Section [2.1](#Sec3){ref-type="sec"}Co-expression of homing molecules and loco-regional deliveryEnhanced trafficking to tumor site\--Limited accumulation at non-lesion sites- Not always technically achievableSection [2.2](#Sec4){ref-type="sec"}Neutralization or resistance to TME-Active reversal of TME immunosuppressionPromotion of CAR-T cell survival at tumor siteActivation restricted to tumor siteTME deprivation of inhibitory signals reactivates endogenous immunityActivity depends on the presence of inhibitory signalSection [2.2](#Sec4){ref-type="sec"}Release of effector cytokines-Paracrine effect on tumor-associated cellsAuto-stimulatory actionInducible expression systems resulting in localized cytokine secretionRejuvenation of host immune responseCytokine with no dose-limiting toxicitiesSection [2.3](#Sec5){ref-type="sec"}Limiting ex vivo cell differentiation\--Superior proliferative capacitiesEffective at lower infusion doses-Readily applicableSection [2.4](#Sec6){ref-type="sec"}Multiple targeting-Targeting of tumor-associated cells\--Multiple ligand-binding capacityTargets are expressed on multiple tumor typesSection [2.5](#Sec7){ref-type="sec"}Switchable CAR-T cells to mitigate toxicity\--Low-dose treatment preserves early memoryTunable activityDelivery of adaptor molecules with different specificitiesOne cellular product*CAR-T* chimeric antigen receptor-T cells, *TME* tumor microenvironment, *-* no impact expected

Yet, a major task is the transition from proof-of-concept studies employing human tumor cell line xenografts into immunocompromised mice to the development of clinically implementable technologies. Indeed, the clinical predictive power of such experimental systems is challenged by the fact that they imperfectly reflect the structural complexity and heterogeneity of established solid human tumors, poorly inform about potential cross-reactivity against healthy human tissues, and provide limited insights about how CAR-Ts interface with the host immune components. Patient-derived xenografts may represent more clinically relevant models but suffer from a variable engraftment rate and poor availability \[[@CR95]\]. In addition, stromal cells from the original human tumor cannot proliferate continuously and are replaced by cells derived from the recipient mouse \[[@CR96]\], thereby preventing investigations into the impact of therapy on TME. Ultimate validation of which combinatorial approaches or defined T cell subsets composition will achieve sustainable effective responses in the human context will only come from future clinical trials carried out to evaluate the resulting conclusion.

Current Treatment of Solid Tumors in the Clinic {#Sec9}
===============================================

Based on the first successes obtained with hematologic indications, and apart from the optimizations of the co-stimulatory domains and overall CAR vector construct and viral vector selection, the majority of clinical studies targeting solid tumors did not further modify the construct, the ex vivo cell culture conditions, or the administration procedures, nor did they use combinations to specifically counteract the hurdles raised by solid tumors. Early studies targeting solid tumors with a single intravenous infusion of first- or second-generation CAR-Ts reported little evidence of clinical effectiveness, while there was some evidence of on-target, off-tumor toxicity seen using CAR-Ts targeting carbonic anhydrase-IX \[[@CR97], [@CR98]\] in renal cell carcinoma or HER2 (human epidermal growth factor receptor 2)/neu in colorectal cancer \[[@CR99]\], which further limited the development of CAR-Ts in the solid tumor field.

As of May 2019, around 160 completed or ongoing CAR-T clinical trials registered with the US National Library of Medicine (ClinicalTrials.gov) are targeting solid tumors (Fig. [1](#Fig1){ref-type="fig"}) (64% of them in phase I, 30% in phase I/II, 3% in phase II, 2% in long-term follow-up, and 1% retrospective studies) over a total of \~ 510 clinical trials in the CAR-T field. The most investigated targets are mesothelin, GD2 (disialoganglioside), HER2, MUC1 (mucin 1), CEA (carcinoembryonic antigen), GPC3 (glypican 3), and EGFRvIII (variant III of the epidermal growth factor receptor \[EGFR\]) (Fig. [2](#Fig2){ref-type="fig"}) and several companies that are currently developing CAR-T approaches for solid tumor indications have reported some preliminary clinical data (Tables [2](#Tab2){ref-type="table"}, [3](#Tab3){ref-type="table"}).Fig. 2CAR-T clinical trials targeting solid tumors. Based on the US National Library of Medicine (ClinicalTrials.gov; excluding long-term follow-up and retrospective studies). *AFP* α-fetoprotein,  *CAR* chimeric antigen receptor, *CAR-T* chimeric antigen receptor T cell, *CEA* carcinoembryonic antigen, *DLL-3* delta-like protein 3, *DR5* death receptor 5, *EGFR* epidermal growth factor receptor, *EGFRvIII* variant III of the epidermal growth factor receptor, *EPCAM* epithelial cell adhesion molecule, *EpHA2* Ephrin type A receptor 2, *FAP* fibroblast activation protein, *FR-alpha* folate receptor-α, *GD2* disialoganglioside, *gp100* glycoprotein 100, *GPC3* glypican 3, *HER2* human epidermal growth factor receptor 2, *IL-13Rα2* interleukin-13 receptor α2, *LMP1* latent membrane protein 1, *MAGE* melanoma associated antigen, *MMP* matrix metalloproteinase, *MUC1* mucin 1, *NKG2D* natural killer group 2 member D, *NY-ESO-1* New York esophageal squamous cell carcinoma 1, *PD-L1* programmed death-ligand 1, *PSCA* prostate stem cell antigen, *PSMA* prostate-specific membrane antigen, *ROR1/2* receptor tyrosine kinase-like orphan receptor 1/2, *TME* tumor microenvironment, *VEGFR-2* vascular epidermal growth factor receptor-2Table 2Ongoing clinical trials evaluating chimeric antigen receptor T cell therapy in solid tumorsAntigenCancerClinicalTrials.gov identifiers per approach^a^Only CARHoming increaseNeutralization of or resistance to immune-suppressive TMEBoosting CAR-T capacitiesMitigation of toxicityNo strategy specific to solid tumorsLoco-regional administrationCheckpoint inhibitionCytokine local release or combinationAny other combination or cell modificationSafety switchesAFPHepatocellular carcinoma, liver*NCT03349255*AXLRenal*NCT03393936*CD117SarcomasNCT03356782CD133Liver, pancreatic, brain, breast, ovarian, colorectal, glioma, sarcomasNCT02541370, NCT03356782, *NCT03423992*CD171 (L1-CAM)Neuroblastoma, ganglioneuroblastoma*NCT02311621*NCT00006480CD20Melanoma*NCT03893019*CD70Renal cell carcinomaNCT02830724CD80/86LungNCT03198052CEAColorectal, breast, lung, gastric, pancreatic, liver metastasesNCT00004178, NCT00673322, NCT00673829, NCT01212887, NCT01723306, N*CT02349724*, *NCT03267173*NCT01109095, *NCT01373047*, *NCT02416466*, *NCT02850536*, *NCT02959151*, *NCT03682744*, *NCT03818165*Claudin18.2Gastric and esophagogastric junction adenocarcinoma, pancreatic adenocarcinoma*NCT03159819*, NCT03302403, *NCT03874897NCT03890198*c-METBreast, hepatocellularNCT03060356, NCT03638206,NCT01837602NCT03672305DLL-3Lung*NCT03392064*DR5HepatomaNCT03638206EGFRGlioma, lung, liver, stomach, colorectal, sarcoma, neuroblastoma*NCT01869166*, NCT02331693, *NCT03152435*, NCT03638167NCT02862028, NCT02873390, NCT03182816,*NCT03542799***NCT03618381NCT03618381**EGFRvIIIBrain and CNS, gliomas, glioblastoma, colorectal, pancreaticNCT01454596, *NCT02209376*, NCT02666248, *NCT02844062*, NCT03267173, NCT03423992, NCT03638206NCT02959151, NCT03283631NCT03170141, NCT03726515NCT02664363EpCAMStomach, liver, gastric, bile duct, colon, nasopharynx, breast*NCT02725125*, *NCT02729493*, NCT02915445, NCT03013712NCT03563326EpHA2GliomaNCT02575261, NCT03423992ErbB ligandsHead and neck*NCT01818323*FAPPleural mesothelioma, lung, breast, ovarian, bladder, pancreaticNCT01722149**NCT03932565NCT03932565**FR-αOvarian, fallopian, peritonealNCT00019136, NCT03585764GD2Neuroblastoma, sarcomas, melanoma, cervical, glioma, lungNCT02761915, NCT02765243, *NCT02919046*, NCT02992210, NCT03170141, NCT03252171, NCT03356782, NCT03356795, NCT03356808, NCT03423992, NCT03535246**NCT01822652**NCT03294954 NCT03635632 **NCT03721068**NCT00085930, NCT01460901, NCT01953900, NCT02439788,**NCT01822652**, *NCT02107963*, NCT03373097,**NCT03721068**gp100Melanoma***NCT03649529**NCT03649529***GPC3Hepatocellular carcinoma, glioma*NCT02395250*, NCT02723942, *NCT02876978*, NCT02905188, NCT02932956, NCT03084380, *NCT03146234*, NCT03198546, *NCT03302403*, *NCT03884751NCT02715362*, NCT02959151, *NCT03130712*HER2Sarcoma, brain and CNS, gliomas, glioblastoma multiforme, breast, ovarian, lung, gastric, pancreatic, colorectalNCT00228358, *NCT00902044*, NCT00924287, *NCT01109095*, NCT01935843, NCT02442297, NCT02547961, NCT02713984, NCT03198052, NCT03267173, NCT03423992, NCT03500991,NCT02959151, *NCT03696030*NCT00889954*NCT03389230*, NCT03740256IL-13Rα2Brain and CNS, gliomas, glioblastoma multiformeNCT00730613, NCT03423992**NCT01082926,** *NCT02208362***NCT01082926**Lewis-YLungNCT03198052, NCT03851146LMP1Nasopharyngeal neoplasmsNCT02980315MAGE-A1/3/4LungNCT03356808, NCT03535246MesothelinPleural mesothelioma, peritoneal mesothelioma, pancreatic, ovarian, lung, breast, endometrial, peritoneal carcinoma, fallopian tube, cervicalNCT01355965, NCT01583686, NCT01897415, *NCT02159716*, NCT02388828, NCT02580747, NCT02792114, *NCT02930993*, NCT03198052, NCT03267173, NCT03323944, NCT03356795, NCT03356808, NCT03535246, *NCT03638193*, NCT03638206, *NCT03799913*, *NCT03814447*, NCT03916679*NCT02706782*, NCT02959151, NCT03054298, NCT03497819NCT03030001, NCT03182803, NCT03545815, NCT03615313, NCT03747965NCT02465983*NCT02414269*MG7Liver metastases*NCT02862704*MMP, Melan A, P16Multiple cancer indicationsNCT03535246MUC1Brain glioma, colorectal, gastric carcinoma, hepatocellular carcinoma, lung, pancreatic, breast*NCT02587689*, *NCT02617134*, *NCT02839954*, NCT03198052, NCT03267173, NCT03356782, NCT03356795, NCT03356808, NCT03633773NCT02959151NCT03170141, NCT03179007, *NCT03525782*, *NCT03706326*MUC16Ovarian***NCT02498912**NCT02498912***NKG2D ligandsColorectal, ovarian, pancreatic, breast, urothelial*NCT03018405NCT03370198NCT03310008*, *NCT03692429*NY-ESO-1Esophageal, fallopian tube, ovarian, peritoneal lung, glioma, melanoma, synovial sarcomaNCT01795976*NCT03638206*NCT03017131PD-L1Glioblastoma multiforme, lung cancer*NCT03330834*, NCT03198052*NCT02937844*PSCAPancreatic and lung cancersNCT03198052, NCT03267173, NCT03873805NCT02959151*NCT02744287*PSMAProstate cancerNCT00664196, NCT01140373, NCT01929239, NCT03185468, NCT03356795NCT03089203ROR-1Breast and lung cancers*NCT02706392*ROR-2Renal carcinomaNCT03393936VEGFR-2Melanoma, renal, colorectal, ovarian, lung, metastatic cancersNCT01218867*AFP* α-fetoprotein, *CAR* chimeric antigen receptor, *CAR-T* chimeric antigen receptor-T cell, *CEA* carcinoembryonic antigen, *CNS* central nervous system, *DLL-3* delta-like protein 3, *DR5* death receptor, *EGFR* epidermal growth factor receptor, *EGFRvIII* variant III of the epidermal growth factor receptor, *EpCAM* epithelial cell adhesion molecule, *EpHA2* Ephrin type A receptor 2, *FAP* fibroblast activation protein, *FR-α* folate receptor-α, *GD2* disialoganglioside, *GPC3* glypican 3, *gp100* glycoprotein 100, *HER2* human epidermal growth factor receptor 2, *IL-13Rα2* interleukin-13 receptor α2, *L1-CAM* L1 cell adhesion molecule, *LMP1* latent membrane protein 1, *MAGE* melanoma associated antigen, *MMP* matrix metalloproteinase, *MUC1* mucin 1, *NKG2D* natural killer group 2 member D, *NY-ESO-1* New York esophageal squamous cell carcinoma 1, *PD-L1* programmed death-ligand 1, *PSCA* prostate stem cell antigen, *PSMA* prostate-specific membrane antigen, *ROR-1/2* receptor tyrosine kinase-like orphan receptor 1/2, *TME* tumor microenvironment, *VEGFR-2* vascular epidermal growth factor receptor-2^a^Italics indicate industry-driven or sponsored; bold indicates a combination of several approachesTable 3Industry-driven clinical trials targeting solid tumorsIndustry sponsorTarget antigen CAR constructTrial (ClinicalTrials.gov identifier)IndicationApproachClinical dataAtara with MSKCCMesothelinscFv.1XX.ζNCT02414269Malignant pleural disease from pleural mesothelioma or secondary metastatic disease (lung and breast cancers)Intrapleural administration of a CAR co-expressing an icaspase-9 safety switchResults presented at the AACR 2019 \[[@CR103]\]*n *= 21, including 14 who received an anti-PD-1 checkpoint blockade agents off protocol, with no toxicity*n *= 19 mesothelioma patients (13 with anti-PD-1), 2 CRs (at 60 and 32 weeks), 5 PR, and 4 SDAurora with BaylorHER2scFv.CD28.ζ(AU101)Phase INCT00902044SarcomaWithout preconditioningAhmed et al. \[[@CR113]\]*n *= 19, 1 PRCell persistence for up to 18 months after infusion3 patients outlived the median survival historic control with a survival of around 3 years90% of the tumor biopsied after treatment were necroticWith CyFlu preconditioningResults presented at ASCO 2017 \[[@CR130]\] and AACR 2019 \[[@CR114]\]*n *= 10, 2 CR, 3 SD1 CR relapsed after 12 months, was reinjected, and is still in remission after 17 months; the other CR patient has been in remission for 32 monthsHER2scFv.CD28.ζ in CMV.pp65 T cells(AU105)Phase INCT01109095Glioblastoma multiformeBi-specific CAR-T (CMV-specific cytotoxic T cells) without preconditioningResults presented at SITC 2015 \[[@CR115]\]*n *= 17 (16 evaluable). 8 OR (1 PR, 7 SD for \> 6 weeks, 8 PD)3 patients in FU up to 30 monthsMedian survival: 11.6 months from infusion and 24.8 months from diagnosisHER2 CMV T cells were detected in the peripheral blood for up to 12 weeks post-infusionAutolusGD2scFv.CD28.ζ(1RG-CART)Phase INCT02761915NeuroblastomaWith CyFluResults presented at AACR 2018 \[[@CR116]\]No clinical responses were seen in first 12 patients but response in many sites of bone/marrow disease for 1 patientBellicum PharmaceuticalsPSCAscFv.CD28.ζ(BPX-601)Phase I/IINCT02744287Pancreatic, gastric and prostate AdenocarcinomaGoCAR^®^-separate inducible switch MyD88/CD40Results presented at ESMO 2018 \[[@CR117]\]*n *= 12 (9 evaluable). 5 SD, 4 PD2 patients with SD had tumor shrinkage \>  20%CARsgen TherapeuticsClaudin 18.2scFv.CD28.ζ CARPhase INCT03159819NCT03874897Gastric and pancreatic adenocarcinomaMultiple infusionsResults presented at ASCO 2019 \[[@CR118]\]*n *= 12 (11 evaluable). 1 CR, 3 PR, 5 SDGPC3scFv.CD28.ζPhase INCT02876978NCT03146234NCT02395250Lung squamous cell carcinomaHCCWith or without preconditioningResults presented at ASCO 2017 \[[@CR119]\]*n *= 13 (HCC, 11 evaluable). 1 PR, 3 SD, 2 PDCellular Biomedicine GroupEGFRscFv.4.1BB.ζPhase I/IINCT01869166Biliary tract cancers and NSCLCWith or without preconditioningGuo et al. \[[@CR120]\] and Feng et al. \[[@CR121]\]*n *= 17 biliary tract. 1 CR, 10 SD. Median PFS 4 months*n *= 11 NSCLC. 2 PR and 5 SD for 2--8 monthsAnalysis of data indicated that the enrichment of Tcm in the infused CAR-T--EGFR cells improved the clinical outcomeCelyadNKG2D ligandsNKG2D.ζ (CYAD-01)Phase I \[[@CR122]\]NCT03018405Colorectal cancer, epithelial ovarian and fallopian tube carcinoma, urothelial carcinoma, TNBC, and pancreatic cancerMultiple IV infusions without prior preconditioningResults presented at SITC 2018 \[[@CR111]\]*n *= 14. 4 SD (3 mCRC + 1 OVA)Colorectal cancerSingle IV infusion with prior CyFlu preconditioningPreliminary results presented at SITC 2018 \[[@CR111]\]*n *= 2. Not yet evaluablePhase INCT03310008mCRCMultiple IV infusions with concurrent FOLFOX chemotherapy regimenResults presented at SITC 2018 \[[@CR111]\]*n *= 3. 1 PRPhase INCT03370198mCRCLoco-regional infusion into the hepatic arteryNot disclosedNKG2D ligandsNKG2D.ζ (CYAD-101)Phase INCT03692429mCRCMultiple IV infusions with concurrent FOLFOX chemotherapy of an allogeneic CAR product (modified with a TCR inhibitory molecule)Not disclosed yetEureka TherapeuticsAFPSecond generation(ET-1402L1)Phase INCT03349255Hepatocellular carcinoma and liver cancerTCR-mimic scFv to target an AFP-peptide/HLA-A2 complex on HCC cancer cellsResults presented at CAR-TCR Summit 2018 \[[@CR123]\]*n *= 6. 1 CR and 2 PRKite Pharma/GileadEGFRvIIIscFv.CD28.ζPhase I/IINCT01454596Malignant gliomasWith CyFlu preconditioning + IV IL-2Not disclosed yetJuno/CelgeneCD171scFv.4-1BB.ζ(JCAR023)NCT02311621Neuroblastoma and ganglioneuroblastomaNot disclosed yetMUC16scFv.CD28.ζ(JCAR020)NCT02498912Ovarian cancerIL-12-secreting CAR-T, IV or IP administeredNot disclosed yetROR-1scFv.4-1BB.ζ (JCAR024)NCT02706392TNBC and NSCLCResults presented at AACR 2018 \[[@CR124]\] and San Antonio Breast Cancer Symposium 2018 \[[@CR125]\]*n *= 5. 4 MR with decreased disease burden patients (2 NSCLC; 2 TNBC), 1 SD (TNBC) for at least 56 days after second infusion*n *= 4 TNBC. 2 SD up to 19 weeks after first CAR-T infusion. 1 PR after second infusion for 14 weeksLeucid BioErbB dimers (HER2, 3 and EGFR)scFv.CD28.ζ(T4 CAR-Ts or LEU-001)NCT01818323Head and neck squamous cell carcinomaCo-expression of a chimeric cytokine receptor (4αβ) which converts the IL-4 signal into a strong and selective growth signalWithout prior preconditioning \[[@CR108], [@CR109]\]Intratumoral administrationResults presented at the CAR-T Congress EU in January 2019*n *= 15. 9 SD1 CR for 2.5 years after subsequent treatment with anti-PD-1 inhibitor pembrolizumabMustang BioHER2NCT03389230Glioblastoma and recurrent gliomaNot disclosed yetNCT03696030Metastatic malignant neoplasm in the brainLoco-regional administrationNot disclosed yetIL-13Rα2scFv.4-1BB.ζ(MB101)NCT02208362Malignant glioma and brain neoplasmsIntracavitary infusionsBrown et al. \[[@CR101]\]*n *= 1. 1 CR of 7.5 monthsNovartis with University of PennsylvaniaMesothelinscFv.4-1BB.ζNCT02159716Metastatic pancreatic cancer, ovarian cancer, or malignant epithelial pleural mesotheliomaNot disclosed yetEGFRvIII-scFv.4-1BB.ζNCT02209376Residual or recurrent gliomaFirst results indicated a good safety profile and first efficacy results were mixed as a result of high heterogeneity of tumor expression and adaptive TME, suggesting the need for a combination with PD-L1 evaluated in another study (NCT03726515).NCT03726515Not disclosed yetSorrento TherapeuticsCEA-CAM5(T-001)NCT02349724Lung, colorectal, gastric, breast, and pancreatic cancersNot disclosed yetNCT03682744Peritoneal carcinomatosis and metastases, colorectal, gastric, breast and pancreatic cancersLoco-regional administrationNot disclosed yetNCT03818165Pancreatic carcinomaLoco-regional administrationNot disclosed yet.NCT02850536HITM-SURELiver metastasesLoco-regional administration via the hepatic artery or splenic vein using the surefire infusion systemResults presented at SITC 2018 \[[@CR126]\]*n *= 5 (4 with pancreatic cancer). 2 patients with no viable liver metastases by PET scan after treatment for up to 12 monthsMedian OS post-treatment was 8.3 months with a mean OS of 9.8 monthsNCT01373047HITMDelivered into the hepatic circulation + systemic IL-2Katz et al. \[[@CR127]\]*n *= 9. 1 SD, OS: 4.5 months with 1 patient still alive at 23 monthsNCT 02416466HITM-SIRHepatic artery infusions and yttrium-90 SIR-spheresResults presented at AACR 2017 \[[@CR128]\]*n* = 6. 3 SD, median OS 6.9 months*AACR* American Association for Cancer Research, *AFP* α-fetoprotein, *ASCO* American Association of Clinical Oncology, *CAR* chimeric antigen receptor, *CAR-T* chimeric antigen receptor-T cell, *CD* cluster of differentiation, *CEA* carcinoembryonic antigen, *CEA-CAM5* Carcinoembryonic antigen-related cell adhesion molecule 5, *CMV* cytomegalovirus, *CR* complete response, *CyFlu* non-myeloablative preconditioning chemotherapy composed of cyclophosphamide and fludarabine, *EGFR* epidermal growth factor receptor, *EGFRvIII* variant III of the epidermal growth factor receptor, *ESMO* European Society for Medical Oncology, *GD2* disialoganglioside, *GPC3* glypican 3, *FOLFOX* leucovorin \[folinic acid\], 5-fluorouracil, and oxaliplatin, *FU* follow-up, *HCC* hepatocellular carcinoma, *HER2* human epidermal growth factor receptor 2, *HLA* human leukocyte antigen, *HITM* hepatic immunotherapy for metastases, *HITM-SIR* HITM with selective internal radiation therapy, *HITM-SURE* HITM with surefire infusion system, *IL* interleukin, *IL-13Rα2* interleukin-13 receptor α2, *IP* intraperitoneal, *IV* intravenous, *mCRC* metastatic colorectal cancer, *MR* mixed response, *MSKCC* Memorial Sloan Kettering Cancer Center, *MUC16* mucin 16, *MyD88* myeloid differentiation primary response 88, *OS* overall survival, *NKG2D* natural killer group 2 member D, *NSCLC* non-small cell lung cancer, *OR* objective response, *OVA* ovarian cancer, *PD-1* programmed death 1, *PD-L1* programmed death-ligand 1, *PET* positron emission tomography, *PFS* progression-free survival, *PR* partial response, *PSCA* prostate stem cell antigen, *ROR-1* receptor tyrosine kinase-like orphan receptor 1, *scFv* single-chain variable Fragment, *SD* stable disease, *SITC* Society for Immunotherapy of Cancer, *Tcm* central memory T cells, *TCR* T cell receptor, *TME* tumor microenvironment, *TNBC* triple-negative breast cancer

In total, only 61 trials (of which 51 are still ongoing) are evaluating one or two strategies specific to targeting solid tumors, with loco-regional administration being the most represented option, followed by TME neutralization (Fig. [2](#Fig2){ref-type="fig"}).

Loco-regional delivery (detailed in Sect. [2.1](#Sec3){ref-type="sec"}) is being or was investigated in 22 trials and is the only option that, to date, has demonstrated clinical activity and, in addition, provides a way to circumvent the potential on-target, off-tumor toxicities by confining transferred cells within their targeted organs. Glioblastoma is, by far, the indication where the results were the most encouraging. Multiple intracranial infusions (to bypass the blood--brain barrier and target tumor cells throughout the entire central nervous system) of first-generation IL-13Rα2-specific CAR-Ts led to transient anti-glioma responses and an encouraging duration of overall survival in the first three patients with recurrent glioblastoma multiforme (GBM) treated in the trial \[[@CR100]\]. A recent case report demonstrated that repeated intracavitary infusions of second-generation IL-13Rα2-specific CAR-Ts further demonstrated regression of all intracranial and spinal tumors, lasting for 7.5 months in one 50-year-old patient with recurrent multifocal GBM \[[@CR101]\]. Of 16 evaluable patients with GBM treated with HER2-specific CARs, one had a partial response lasting for more than 9 months and seven had stable disease (SD) ranging in duration between 8 weeks and 29 months \[[@CR102]\] (sponsored by Mustang Bio).

The next most important strategies being investigated are approaches to neutralizing or resisting the effects of the TME (18 trials) and/or reverting the TME to a stimulatory environment through the intrinsic release of cytokines (six trials) (see Sect. [2.2](#Sec4){ref-type="sec"} for both approaches). As an example, one trial run by the Memorial Sloan Kettering Cancer Center and targeting pleural mesothelioma patients (recently licensed by Atara) with intrapleural administrations of mesothelin-targeting CAR-Ts observed two complete responses (CRs) out of 14 patients after combination with a checkpoint inhibitor \[[@CR103]\].

A good example of a trial on a CAR-T that can mitigate toxicity (approach detailed in Sect. [2.5](#Sec7){ref-type="sec"}) is Bellicum Pharmaceuticals' autologous prostate stem cell antigen (PSCA)-targeting CAR-T product (BPX-601). This CAR-T employs a rimiducid-inducible myeloid differentiation primary response 88 (MyD88)/CD40 co-activation switch to augment T cell proliferation and persistence, which provides control over the degree of activation of the CAR-Ts through adjustments to the schedule of rimiducid administration, but still in a tumor-dependent manner. Results from a phase I study evaluating BPX-601 in PSCA-positive metastatic pancreatic, gastric, or prostate cancer patients with or without prior preconditioning were presented at the American Association of Clinical Oncology (ASCO) meeting in 2019 \[[@CR104]\] and reported rimiducid-dependent cell expansion, persistence, and cytokine secretion with no dose-limiting toxicity or cytokine release syndrome. After BPX-601 + rimiducid (15 patients treated), the best responses were eight SD and three progressive disease (one patient was non-evaluable). The trial is still ongoing with a more complete lymphodepleting regimen.

Other encouraging results were observed in clinical trials that include a combination of strategies (described in Sect. [2.6](#Sec9){ref-type="sec"}). A first example is a trial targeting pediatric neuroblastoma with single or multiple intravenous infusions of CAR-T-specific subpopulations (approach detailed in Sects. [2.3](#Sec5){ref-type="sec"} and [2.5](#Sec7){ref-type="sec"}). There was one CR in the six patients treated with three intravenous infusions of CD8^+^ cytotoxic T lymphocytes co-expressing a CD171-targeting CAR and a selection-suicide expression enzyme, followed by additional treatment with salvage chemotherapy \[[@CR105]\]. Similarly, three of 11 high-risk neuroblastoma patients with active disease achieved CR following infusions of Epstein Barr virus-specific cytotoxic T lymphocytes and CD3-specific antibody OKT3-activated T cells expressing GD2-targeting CAR-Ts, and persistence of cells beyond 6 weeks was associated with superior clinical outcome \[[@CR106], [@CR107]\].

Kings College, London has developed another combined approach with genetically engineered T cells (T4 CAR-Ts or LEU-001), which co-express two chimeric receptors: one CAR-T specific for ErbB ligands (HER2, HER3, and EGFR) and a second chimeric cytokine receptor (4αβ) which converts the IL-4 signal into a strong and selective growth signal, i.e., a CAR-T product that combines several approaches: multiple targeting and reshaping of the TME through release of pro-inflammatory cytokines (see Sects. [2.2](#Sec4){ref-type="sec"}, [2.4](#Sec6){ref-type="sec"}, and [2.6](#Sec8){ref-type="sec"}). A clinical study (ClinicalTrials.gov identifier NCT01818323) is currently evaluating intratumoral administration of T4 CAR-Ts for patients with head and neck squamous cell carcinoma without prior lymphodepletion \[[@CR108], [@CR109]\]. Results made public at the CAR-T Congress EU in January 2019 revealed nine of 15 injected patients with SD, with potential survival improvement. One patient received further treatment with the anti-PD-1 inhibitor pembrolizumab and was in CR 2.5 years after pembrolizumab treatment, suggesting a combination of their CAR-T therapy and an anti-checkpoint inhibitor might be the way to improve efficacy.

Celyad is also involved in CAR-T development for solid tumors. Based on the broad (eight-ligand) targeting capability of NKG2D CAR-Ts that target cancer cells and also stressed stromal cells within the solid tumor environment (approach detailed in Sect. [2.4](#Sec6){ref-type="sec"}), in 2016 Celyad initiated a complete clinical development plan first based on its lead product candidate, CYAD-01 (also known as NKR-2), a 'first-generation' CAR (comprising the full-length human NKG2D receptor fused to the intracellular domain of CD3ζ) functioning rather like a second-generation CAR-T thanks to its interaction with the naturally endogenously expressed co-stimulatory molecule DAP-10 (DNAX-activating protein 10) at the T cell surface. Three studies evaluating the CYAD-01 product are directed against solid tumor indications \[[@CR110]\]. Preliminary data indicated signs of clinical activity following multiple intravenous administrations of CYAD-01 without prior lymphodepletion preconditioning in patients with colorectal cancer or ovarian cancer (four SD over the 14 patients recruited in the solid tumor arm \[[@CR111]\]). The second trial is SHRINK (NCT03310008), which is evaluating CYAD-01 administered concurrently to a standard neoadjuvant FOLFOX (leucovorin \[folinic acid\], 5-fluorouracil, and oxaliplatin) chemotherapy regimen in metastatic colorectal cancer (mCRC) with the aim of improving CYAD-01 engraftment in addition to the TME remodeling induced by the chemotherapy (approach detailed in Sect. [2.2](#Sec4){ref-type="sec"}). Preliminary data presented at SITC (Society for Immunotherapy of Cancer) 2018 indicated encouraging signs of activity with a partial response observed in one of three patients \[[@CR111]\]. The LINK study (NCT03370198) focuses on loco-regional infusion into the hepatic artery of the CYAD-01 cells in patients with mCRC (approach detailed in Sect. [2.1](#Sec3){ref-type="sec"}).

Importantly, Celyad also developed an allogeneic analog of CYAD-01, using a TCR inhibitor molecule (TIM) coded within the vector construct to control the risk of GvHD, called CYAD-101, which is currently being evaluated in a phase I study with a similar study design as the SHRINK study---the alloSHRINK study (NCT03692429). At this time, this is the only clinical trial with an allogeneic CAR-T in a solid tumor, while there are still very limited allogeneic programs specifically designed for solid tumors in preclinical development (approach detailed in Sect. [2.6](#Sec8){ref-type="sec"}).

Methodology {#Sec10}
===========

For the pie charts in Figs. [1](#Fig1){ref-type="fig"} and [2](#Fig2){ref-type="fig"}, a list of clinical trials evaluating CAR-T therapies was compiled from the ClinicalTrials.gov registry and the number of trials targeting specific organ classes or using a specific approach was counted for each represented option. Only for the pie chart representing the target antigens used in trials targeting solid tumors (Fig. [2](#Fig2){ref-type="fig"}; left chart), the numbers represented consider all trials evaluating that specific target antigen, i.e., where a trial is evaluating several targets in parallel, it is counted individually for each target (as detailed in Table [2](#Tab2){ref-type="table"}).

Conclusions {#Sec11}
===========

CAR-T therapy for the treatment of solid tumors is currently being evaluated in approximately one-third of the clinical trials of CAR-T approaches, with several companies now moving into the area (Table [3](#Tab3){ref-type="table"}). While the number of patients with solid tumors dramatically outnumber those with hematological malignancies (Fig. [1](#Fig1){ref-type="fig"}), CAR-T therapies targeting solid cancers have yet to demonstrate the clinical activity achieved with hematological indications \[[@CR112]\].

Considerable efforts have been made in recent years to develop new approaches to overcome the hurdles raised by solid tumors and optimize the CAR-T therapy for these specific indications, including strategies to increase the tumor accessibility and infiltration of CAR-Ts within the tumor site, neutralize and/or modulate the immunosuppressive TME, improve the CAR-T functions, and/or mitigate potential toxicities.

Finally, apart from those strategies to make CAR-Ts work in solid tumors, there will also be the need to make those technologies more affordable for their clinical usage to become widespread. By using healthy donor cells instead of each patient's cells, allogeneic CAR-T could be one way of reaching this goal.

Still, to date, despite a few interesting results, there is little evidence that CAR-T therapy can advance as a standard treatment option for patients with solid tumors. Therefore, a key question is whether the current CAR-T structure utilizing one of the strategies discussed here is able, for example, to circumvent all of the mentioned hurdles, or whether those CAR-Ts will require additional fundamental changes in their architecture to eventually be sufficiently active against solid tumors.

No external funding was used in the preparation of this review.
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